New Results: Analysis of the Government’s CGM Subsidy Scheme
An analysis of the impact of the Australian Government’s continuous glucose monitoring (CGM) subsidy scheme for people aged under 21 has recently been published in the journal Diabetes Care.
Led by Prof Tim Jones and the Australasian Diabetes Data Network (ADDN) Study Group, the study found that those who registered for the subsidy had significant improvements in their glucose management and health outcomes. Read on to find out more about these exciting results.
What did this study involve?
This study was designed to assess the impact of the Australian Government’s CGM subsidy scheme, introduced in 2017 for people with T1D aged younger than 21 years.
By analysing data recorded in the ADDN, researchers were able to determine the rate of CGM uptake among people eligible for the subsidy, and whether their health outcomes improved after using CGM technology.
What were the results of this study?
Prior to the subsidy scheme, the usage rate of CGM in people aged under 21 in Australia was less than 5%. After the subsidy, this increased to 79%. Of those with documented CGM use, 65% of people used CGM more than 75% of the time, with only 31% using CGM less than 25% of the time.
After 6 months of using CGM, people who took part in the scheme were more likely to have an HbA1c of less than 7%. This likelihood continued to improve throughout the 2-year study period. Average HbA1c among young people taking part in the CGM scheme decreased by 0.3-0.5% overall. In the group of people who did not register for CGM use, there was an increase in average HbA1c over the same period.
Importantly, young people who took part in the CGM scheme were less likely to experience severe hypoglycaemia throughout the length of the study. Among those who used CGM more than 75% of the time, rates of diabetic ketoacidosis (DKA) were also lower compared to those using CGM less than 25% of the time.
What does this mean for people with T1D?
This study provides real-world data showing that subsidising CGM access increases its usage, which in turn improves health outcomes for young people with T1D. Data from real-world scenarios such as this is of huge importance to funders, policy makers and clinicians, and for people with type 1 diabetes to make informed decisions about their treatment options.
Where did the data come from?
ADDN is a registry that captures deidentified clinical data from 18 diabetes centres across Australia and New Zealand. ADDN captured data from 3,060 people with T1D over the course of this study, with 2,625 of those people registering for the government’s CGM scheme.
What happens next?
This data will be a powerful tool for JDRF to use in its campaign to enable access to subsidised CGM for all people with type 1 diabetes. It provides evidence to strengthen our argument that technology provides a vital role in managing T1D and should be available to everyone, regardless of age. We continue to advocate for this access and work with the Government and Department of Health to develop new pathways for access to technology.
JDRF Australia welcomes significant commitment to improving lives of Australian type 1 diabetes (T1D) community
Coalition commitment of $273.1M will make technology access a reality for 130,000 Australians living with T1D. JDRF, Australia’s largest organisation dedicated to T1D research and advocacy, welcomes the significant commitment to T1D technology access announced today by Prime Minister Scott Morrison. Currently, many people lose access to this technology, which is shown to improve short- […]
The Access For All Journey
The campaign for increased access to continuous glucose monitoring devices (CGMs) for the T1D community has been a long and winding road. 6 years ago, there was no government reimbursement for CGMs at all. Thanks to consistent advocacy and campaigning from leading diabetes organisations, the landscape has changed significantly– transforming the lives of many people […]
Meet Ashley Hanger, Founder of Australia’s first diabetes subscription box!
After seeing the challenges of type 1 diabetes in her partner, she found her passion providing support to people living with chronic illness. She founded Stripped Supply, Australia’s first diabetes subscription box, with a vision to give control back to the patient and make diabetes healthcare more accessible. We recently chatted to Ashley on her experiences […]
Annual Giving Day FAQs
Our Annual Giving Day is coming up on 9 June 2022. That’s so soon! But, what does it all mean and how can you get involved? Keep reading as we answer your frequently asked questions. What is JDRF Australia’s Annual Giving Day? Our Annual Giving Day is a chance for the dedicated type 1 diabetes […]
How You Can Help Make Type 1 Diabetes Research a Reality
JDRF has an ambitious vision — a world without type 1 diabetes (T1D). We are the biggest funder of type 1 diabetes research globally and in Australia. In order to achieve this with such a complex autoimmune disease, we must take a strategic, multi-level and collaborative approach to research. JDRF has embarked on an extensive […]